الصفحة الرئيسية>>Signaling Pathways>> Others>>Seviteronel R enantiomer (VT-464 (R enantiomer))

Seviteronel R enantiomer (VT-464 (R enantiomer)) (Synonyms: VT-464 (R enantiomer))

رقم الكتالوجGC33911

Seviteronel R enantiomer (VT-464 (R enantiomer)) (VT-464 R enantiomer) هو R enantiomer لـ Seviteronel (VT-464) ، وهو مثبط قوي لياز CYP17 (h-Lyase IC50 = 69 نانومتر) ؛ Seviteronel (VT-464) R enantiomer' ؛ نشاط غير معروف.

Products are for research use only. Not for human use. We do not sell to patients.

Seviteronel R enantiomer (VT-464 (R enantiomer)) التركيب الكيميائي

Cas No.: 1375603-38-5

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
283٫00
متوفر
2mg
214٫00
متوفر
5mg
321٫00
متوفر
10mg
459٫00
متوفر
50mg
1379٫00
متوفر
100mg
1930٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Seviteronel (VT-464) R enantiomer is the R enantiomer of Seviteronel (VT-464), which is a potent CYP17 lyase inhibitor(h-Lyase IC50=69 nM); Seviteronel (VT-464) R enantiomer's activity is unknown.

[1]. Rafferty SW, et al. Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors. Bioorg Med Chem Lett. 2014 Jun 1;24(11):2444-7. [2]. Sankar N. Maity, et al. Abstract 4772: Efficacy of VT-464, a novel selective inhibitor of cytochrome P450 17,20-lyase, in castrate-resistant prostate cancer models. Cancer Research: April 15, 2013; Volume 73, Issue 8, Supplement 1

مراجعات

Review for Seviteronel R enantiomer (VT-464 (R enantiomer))

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Seviteronel R enantiomer (VT-464 (R enantiomer))

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.